Of all human carcinomas, breast cancer (BrCa) is worldwide the most frequently occurring tumor in women [1] . Most breast cancer patients succumb to their disease as a result of tumor metastasis [2, 3] . It is therefore important to elucidate the factors which effect BrCa progression, therapy resistance and metastasis. Accumulated evidence could demonstrate that breast cancer is a very complex and intrinsically heterogeneous disease, which progresses through accumulation of genomic aberrations that enable development of cancer-specific pathophysiological changes such as unlimited growth in even nutrient limited environments and metastasis to distant organs [4, 5] . Recent advances in technology, such as DNA and RNA microarrays, have allowed to deconvolute some of the heterogeneity and complexity of somatic BrCa genetics. Using RNA microarrayderived expression data, breast cancer has been classified into five molecular subtypes: normal breast like, luminal A, luminal B, HER2 + / ERBB2 + , and basal-like. Among these molecular subtypes, basal-type breast cancer is associated with a most aggressive growth and poor prognosis [6] . Based on these molecular findings, some improvements have been made in diagnosis and treatment of breast cancer. However, for most patients, the prognosis and disease-free survival times have not changed dramatically. This is likely due to mechanisms by which gene amplifications affect survival or other aspects of cancer pathophysiology most of which are not well understood. Thus, mechanistic and functional studies of molecular changes in breast cancer-are urgently required.
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The long arm of human chromosome 20, termed 20q, is frequently found amplified in a wide variety of human solid tumors among them BrCa [7] [8] [9] [10] [11] [12] . Several studies reported that amplification of 20q is associated with poor clinical outcome of cancer and serve as an indicator for cancer progression and metastasis [7, 13] . Multiple genes encoded on 20q have been identified as candidate oncogenes in BrCa including Aurora-A kinase (AURKA) [14, 15] , ZNF217 [16] , UBE2C [17] and TPX2 [18] . AURKA is a key regulator of chromosome segregation and cytokinesis [14, 15, 19] . Over expression of AURKA in tumors is correlated with clinically aggressive disease [20] . A wealth of functional data exists showing that over expression of AURKA leads to centrosome amplification, chromosomal instability and oncogenic transformation [14, 15, [21] [22] [23] . Furthermore, over expression of AURKA in transgenic mouse models resulted in the development of mammary gland tumors [24, 25] . These data indicate that AURKA possesses oncogenic activity and may be a valuable therapeutic target in cancer therapy [26, 27] . Consequently, several small-molecule inhibitors of Aurora-A kinase have been developed and are currently undergoing clinical trials [28] .
We conducted a meta-analysis of AURKA expression in human breast cancer samples using Breast Cancer Gene-Expression Miner v3.0 (bc-GenExMiner v3.0) software [29, 30] . Consistent with recent reports [31] , patients with high AURKA mRNA expression levels (greater than median expression) had significantly decreased survival (any event [AE]) compared to those with low AURKA mRNA levels (less than median expression) (hazard ratio (HR) =1.62; 95% CI: 1.44-1.83; p<0.0001) ( Figure 1A) . Surprisingly, we also found that high AURKA mRNA levels significantly decreased metastatic relapse (MR)-free survival (HR=1.75; 95% CI: 1.50-2.05; p<0.0001) ( Figure 1B ).
Estrogen receptor (ER) and nodal status in breast cancer is an important predictor of recurrence and greatly influences treatment regimens. We, therefore, performed univariate Cox proportional hazards model analysis on each of the 18 possible pools corresponding to every combination of population (nodal and estrogen receptor status) and event criteria (MR or any event [AE]) to assess the prognostic impact of AURKA expression on patients with different ER and nodal statuses. As summarized in table 1, we found that high AURKA expression shortened both AE-and MR-free survival only in the groups of ER + or ER m patients, not in the group of ER -patients. To further clarify these results, we performed a subset analysis of AURKA in ER-positive and ER-negative tumors. High levels of AURKA expression were significantly associated with shorter AE-and MRfree survival in patients with ER-positive, but not ER-negative tumors ( Figures 1C-F) .
The molecular subtype of human BrCa is another important prognostic factor. Therefore, the tumors were assigned into normal-like, luminal A, luminal B, HER2 + , and basal-like subtype based on criteria described by Hu et al. [32] . This resulted in samples assigned as normallike (n=451), luminal A (n=720), luminal B (n=507), HER2 + (n=255), basal-like (n=652), or unclassified (n=329). Overall, expression levels of AURKA were highest in basal-like tumors and lowest in normal-like tumors. However, it is interesting to note that, among these groups, in normal-like, luminal A as well as B subtypes, patients with high expression levels of AURKA presented with significantly decreased AE-free survival (in normal-like subtype: HR=1.39; 95% CI:1. In conclusion, the meta-analysis of transcriptional profiles showed that AURKA expression levels may be a useful prognostic factor for patients with ER-positive, normal-like and luminal A-or B-type BrCa tumors. 
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